Journal of Hematology & Oncology 2022

3 papers
In 2022, the Journal of Hematology & Oncology focused on systemic inflammation, targeted cancer therapies, and diagnostic monitoring. Research addressed the mitigation of organ failure in hyper-inflammatory states, including the use of soluble CD24 to treat COVID-19-associated immunopathology. Methodological themes emphasized hub gene identification in biological interaction networks and strategies to bridge the preclinical translational gap in drug development. In oncology, the journal featured advancements in monoclonal antibody design and liquid biopsy applications. Research included the evaluation of FTL004, an anti-CD38 antibody for multiple myeloma and non-Hodgkin lymphoma that aims to reduce red blood cell binding and address the problem of fratricide in immune defense. Furthermore, studies explored using circulating tumor DNA to detect minimal residual disease in resectable non-small-cell lung cancer. Contributing authors included Anjun Ma, Anna E. Vilgelm, and Chelsea Bolyard. These publications reflect a broader trend toward refining targeted therapies and improving the precision of post-treatment monitoring.

Top Research Directions

The 4 research directions with Journal of Hematology & Oncology 2022 papers, ranked by paper count, next to 2021. Share is the fraction of the edition’s papers in the direction.

#Direction20222021Share 2022Share 20212021 rank
1Network Centrality for Identifying Regulatory Hub Genes1033.3%0.0%—
2Suppressing Cytokine Storms to Prevent Sepsis-Induced Organ Failure1033.3%0.0%—
3Therapeutic Suppression of the NF-κB and NLRP3 Pathways1033.3%0.0%—
4Why Small Sample Single Center Studies Fail to Generalize1033.3%0.0%—

Download all directions as CSV

Institutions

Institutions credited by Journal of Hematology & Oncology 2022 papers: a paper credits every institution named in its affiliations, once. 7 institutions share 2 credited papers.

#InstitutionPapersShare20212021 rank
100x43yy22 150.0%0—
205jcvqz82 150.0%0—
3Medical University of South Carolina 150.0%0—
4Sichuan University 150.0%0—
5The Ohio State University 150.0%0—
6The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute 150.0%0—
7The Ohio State University Wexner Medical Center 150.0%0—

Download all institutions as CSV

About this data

Papers. Journal of Hematology & Oncology 2022 lists 3 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2021 use shares, since the edition went from 5 to 3 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 2 of 3 papers (66.7%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-17 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Hematology & Oncology 2022”, https://lacuna.tiptreesystems.com/venue/journal-of-hematology-oncology/2022.

Top Authors

AuthorPapers
Min Wu1
Yu Meng1

Papers

Title
Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer
FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology